NEW DELHI : Using fluvoxamine to treat high-risk outpatients with early-diagnosed covid-19 reduced the need for prolonged observation in an emergency setting or hospitalisation when compared to a control group who received a placebo during a randomised clinical trial, the results of which were published in The Lancet Global Health on Wednesday.
Fluvoxamine is currently used to treat mental health conditions such as depression and obsessive-compulsive disorders. It was chosen for study as a potential treatment for covid-19 due to its anti-inflammatory properties. “Fluvoxamine may reduce the production of inflammatory molecules called cytokines, that can be triggered by SARS-CoV-2 infection," Dr Angela Reiersen, Associate Professor of